No Data
Nomura: Profits in China's internet plus-related industry better than expected, focus on ai in the second half of the year.
Shalong Shi, head of the Nomura China Internet and New Media Research Department, said that investors are relatively cautious about the mainland's internet plus-related industry, but think that the fundamentals of the industry are still healthy.
Alibaba responds to allegations of counterfeit goods at Daway Pharmacy's overseas stores: all products are US imported products, ensuring legitimacy and legality.
Sina Technology News, July 4th afternoon, recently, some consumers reported to the media that during the 618 period, they purchased 2 boxes of American Geese brand Peiquan Jinghua Nutritional Oral Liquid at Tmall Ali Health Pharmacy's overseas store. However, after receiving the goods, consumers doubted the absence of "smart anti-counterfeiting traceability code" on the product packaging, and believed that the taste and packaging of the product were different from what they had purchased on the official website before, suspecting that they had bought fake products. In response to the suspicion of selling fakes, Ali Health responded that it had contacted consumers to confirm the specific situation for the first time, and communicated with the American Geese brand. It has been confirmed that Ali Health Pharmacy is selling
Hong Kong Shares Rebound 2.9% Amid Positive Sentiment
Hong Kong stocks abnormality | Ali Health (00241) rose more than 4%, 2024 fiscal year performance exceeded expectations, Goldman Sachs pointed out that its profit margin visibility is high.
According to the Finance and Economics APP, the ali health (00241) has risen by over 4%, reaching 4.13% at the time of publication, with a trading volume of 90.3826 million Hong Kong dollars. On the news, ali health's revenue for the period ending in March 2024 was 27.027 billion yuan; net income was 883 million yuan, up 64.6% year-on-year, and adjusted net income was about 1.438 billion yuan, up 90.8% year-on-year. Haitong International believes that the company's profits exceed market expectations, and the profit margin for the fiscal year 2025 is expected to further improve. In terms of internet plus-related services online and offline, prescription outflow, and online medical insurance policies.
Goldman Sachs reaffirms their "buy" rating for Ali Health (00241), with a target price of HKD 4.4.
Goldman Sachs believes that ali health's profit margin will be visible in the next two years.
Ali Health (00241) granted a total of 3,700,700 stock options and 73,600,600 restricted stock units.
Alibaba Health (00241) announced that on June 14th, 2024, the company granted a total of 3.7007 million subscription rights and a total of 73.6006 million restricted share units to 2 affiliated grantors according to the terms of the share incentive plan, and must wait for acceptance before becoming effective for 576 grantees.
No Data
